Decision making for adjuvant chemotherapy in stage III colon cancer is based on the TNM system. It is well known that prognosis worsens with higher pN classification, and several recent studies propose superiority of the lymph node ratio (ln ratio) to the TNM system. Therefore, we compared the prognosis of ln ratio to TNM system in our stage III colon cancer patients.
Methods
A total of 939 patients underwent radical surgery for colorectal cancer between January 2000 and December 2009. From this pool of patients, 142 colon cancer stage III patients were identified and taken for this analysis. Using martingale residuals, this cohort could be separated into a group with a low ln ratio and one with a high ln ratio. These groups were compared to pN1 and pN2 of the TNM system.
Results
For ln ratio, the cutoff was calculated at 0.2. There was a good prognosis of disease-free and cancer-related survival for the N-category of the TNM system as well as for the lymph node ratio. There was no statistical difference between using the N-category of the TNM system and the ln ratio.
Conclusions
There might not be a benefit in using the lymph node ratio rather than the N category of the TNM system as long as the number of subgroups is not increased. In our consideration, there is no need to change the N categorization of the TNM system to the ln ratio.
The online version of this article (doi:10.1186/1477-7819-11-79) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no conflicts of interest.
Authors’ contributions
LS and AKE conceived and coordinated the study, collected patients’ data and participated in the statistical analysis. LS drafted the manuscript. MG and EK participated in preparing and drafting the manuscript. All authors read and approved the final manuscript.
Abkürzungen
ASA
American Society of Anesthesiologists
CRC
Colorectal cancer
CRS
Cancer-related survival
DFS
Disease-free survival
ln ratio
Lymph node ratio
UICC
Union for International Cancer Control.
Background
Colorectal cancer (CRC) is one of the most important causes of cancer-related death in the western world. In Germany, approximately 71,400 patients develop CRC per year [1]. Most cancer related deaths are not caused by the primary cancer site, but by distant metastasis. However, patients without distant metastasis at the time of surgery (UICC I to III) still have improvable 5-year survival rates between 41% and 96% [2, 3].
Adjuvant or palliative (radio) chemotherapy is generally recommended for UICC III and IV tumors despite the associated toxicities [4, 5]. Patients’ outcomes vary widely between stages with a worsen outcome from stage I to IV, but also within each stage. So far, indication for adjuvant therapy is based on the TNM system and therefore basically on the lymph node status. Several recent studies propose superiority of the lymph node ratio (ln ratio) to the TNM system in prognosis of colorectal cancer [6‐11]. The ln ratio is the ratio of the number of positive nodes to the total number of nodes excised. In this study we compared retrospectively the prognosis of ln ratio to TNM system in our stage III colon cancer patients in terms of disease-free survival (DFS) and cancer-related survival.
Anzeige
Methods
Patients
From January 2000 to December 2009, 939 patients underwent radical surgery for CRC in the Department of General, Thoracic, Vascular und Transplantation Surgery. All patients were treated according to standard treatment guidelines [12]. A preoperative anesthesiological evaluation was obtained according to the American Society of Anesthesiologists (ASA) general classification [13] to determine state of health and comorbidity. Preoperative staging involved endoscopy and biopsy, abdomen ultrasound and chest radiography or computer tomography of abdomen, chest or both.
Patients were staged according to the TNM system [14]. Clinical data were retrieved retrospectively. Data recorded included gender, type of admission, comorbidities, ASA score, tumor characteristics, type of resection, morbidity and 30-day mortality. Follow-up information was recorded regarding recurrence and distant metastasis, overall survival and cancer-related survival as well as information about adjuvant therapy in early 2011. Follow-up examinations were carried out in cooperation with the referring physicians according to the German S3 guidelines for colorectal cancer [12] and provided a comprehensive and complete data collection.
From this pool of patients, all 142 patients with stage III colon cancer were identified and included in this study.
The study was approved by the Medical Ethical Committee of Rostock University.
Anzeige
Comparing lymph node ratio to N category of the TNM system and statistical analysis
To be able to compare the N category of the TNM system to the ln ratio, we decided to separate the ln ratio of all patients into two groups. Therefore, martingale residuals [15] were calculated and represented by a smoothed residual plot [16] to determine if and which cutoff value of the ln ratio would allow the best separation of the groups of patients with worse and better survival.
Statistical analysis was performed using Statistical Package for Social Science (SPSS™) version 15.0. (http://www.spss.com). Statistical analysis was done using Pearson’s chi-square test of Fisher’s exact test. Survival curves were calculated according to the Kaplan-Meier method. Survival curves were tested for significant differences using the log-rank test. A P value of <0.05 was considered as statistically significant. Additionally, further analysis was preformed for the N category of the TNM system and the ln ratio.
Results
From 939 patients a cohort of 142 stage III colon cancer patients was identified. Patients and tumor characteristics are shown in Table 1. On average, there were 23.2 lymph nodes harvested and of these, 4 lymph nodes tested positive for metastasis. In the specimens of 13 patients, fewer than 12 lymph nodes were analyzed. Follow-up time was slightly less than 4 years (mean), and just about one-third of all patients developed recurrence of cancer; 30% of ALL patients died.
Table 1
Patients’ and tumor characteristics of the 142 patients included in the analysis
142 Patients (%)
Mean age (years), (range)
70.0 (37 to 94)
Gender ratio (f/m)
1 : 1
(50:50)
Localization
Cecum
19
(13.4)
Right hemicolon
37
(26.1)
Transverse colon
20
(14.1)
Left hemicolon
8
(5.6)
Sigmoid colon
58
(40.8)
Comorbidities
117
(82.4)
Emergency surgery
25
(17.6)
ASA Score
1 to 2
71
(50.0)
3 to 4
71
(50.0)
Tumor characterization
T1
3
(2.1)
T2
14
(9.9)
T3
64
(45.1)
T4
61
(43.0)
R1/2
10
(7.0)
N1
80
(56.3)
N2
62
(43.7)
Lymph nodes examined
23.16
± 9.33
Lymph nodes positive
4.04
± 4.15
V0
73
(51.4)
L0
76
(53.5)
G1/2
111
(78.2)
Adjuvant chemotherapy
126
(88.7)
Follow-up (years)
3.85
±2.81
Recurrence
48
(33.8)
Died of disease
43
(30.3)
ASA, American Society of Anesthesiologists.
Estimated cancer-related 5-year survival was 66.8% and estimated 5-year disease-free survival was 64.2%.
To determine, if there was a potential benefit of calculating the lymph node ratio rather than using the N category of the TNM system, we separated the patient cohort into two groups of lymph node ratios using the martingale residuals analog to the two groups of the N category of the TNM system. The cutoff was at 0.2 positive to all examined lymph-nodes (shown in Figure 1).
×
A total of 88 patients had a lymph node ratio below 0.2, but only 80 patients had an N1 category. There was a good prognosis of disease-free and cancer-related survival for the N category of the TNM system (Figures 2 and 3) as well as for the lymph node ratio (Figures 4 and 5). But as shown in the figures and posted in Table 2, statistically, differentiation was stronger using the N category of the TNM system.
×
×
×
×
Table 2
Comparison of lymph node ratio (LNR) and pN category of the TNM system for disease-free survival (DFS) and cancer-related survival (CRS)
DFS (%)
Mean DFS (years)a
95% CI*
P
LNR
<0.20
73.9
7.54
6.60 to 8.48
0.008
≥0.20
53.8
5.35
4.05 to 6.65
N
1
78.8
8.07
7.13 to 9.02
< 0.001
2
50.0
4.85
3.82 to 5.87
CRS (%)
Mean CRS (years)*
95% CI*
P
LNR
<0.20
78.4
7.92
7.01 to 8.84
0.007
≥0.20
55.8
5.85
4.61 to 7.09
N
1
78.8
8.18
7.23 to 9.13
0.002
2
58.1
5.41
4.53 to 6.29
aEstimation is limited to longest follow-up time.
There is no statistical difference between pN category of the TNM system and the ln ratio, although the differences in our cohort are bigger for the pN category of the TNM system, as is shown by a lower P value. It is noteworthy that 12 patients with pN1 were categorized in the high ln ratio group, and 20 patients with pN2 were categorized in the low ln ratio group.
Discussion
We retrospectively analyzed whether it would be beneficial to determine the lymph node ratio rather than the N category of the TNM system in prognosis of colon cancer. Therefore, we picked 142 stage III colon cancer patients from a cohort of 939 colorectal cancer patients who were operated on over a 10-year period. In comparison to other reports [6], the fraction, Stage III patients in comparison to all (I to IV) patients) is rather small but the number of examined lymph nodes is rather high [8, 10] as is the percentage of patients receiving adjuvant chemotherapy [17].
For easier comparison of N stages to lymph node ratio, we decided to calculate two groups of lymph node ratios. By doing so, there is no superiority in predicting disease-free and overall survival of the lymph node ratio to the N category of the TNM system. Other authors split patient cohorts by random or percentiles rather than calculating groups [6, 7, 9, 11]. By using more groups, the lymph node ratio gains in precision of prognosis [6, 7, 11], but if more subgroups were established in the N category, precision would presumably rise there as well. So, in our opinion, the only possibility for comparing the two approaches is to use the same number of groups.
To exclude the bias of neoadjuvant treated patients, we decided not to include rectal cancer patients in the analysis. In rectal cancer patients, the number of pathologically diagnosed lymph nodes is frequently lowered after neoadjuvant treatment in comparison to patients not treated with neoadjuvants [18]. Therefore, all rectal cancer patients were excluded from this analysis. Other authors used a stage I to IV colorectal cancer cohort over many years to show the advantage of the lymph node ratio [11]. The disadvantage of this particular approach is that there are many patients included who do not have lymph node metastasis at all, have distant metastasis synchronously and that patients were operated over a long time period. Within this period, surgical techniques might have changed substantially, and therefore, it might be difficult to compare patients’ courses of the disease.
Anzeige
Conclusions
Conclusively, we show with a rather simple approach, that using the lymph node ratio rather than the N category of the TNM system is not beneficial in terms of predicting overall and disease-free survival. Of course there will be an advantage by increasing the number of subgroups within the category - in the N category of the TNM system as well as within the lymph node ratio. In our consideration, there is no need to change the categorization toward the lymph node ratio.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The authors declare that they have no conflicts of interest.
Authors’ contributions
LS and AKE conceived and coordinated the study, collected patients’ data and participated in the statistical analysis. LS drafted the manuscript. MG and EK participated in preparing and drafting the manuscript. All authors read and approved the final manuscript.
Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.